Topotecan Episcleral Plaque for Treatment of Retinoblastoma

Phase 1 Completed 26 enrolled The Hospital for Sick Children

NaSingle-groupOpen-labelTreatment

Summary

This single site, single-arm, non-randomized, dose escalation phase I toxicity clinical trial will assess primarily the safety and secondarily the efficacy of episcleral topotecan in patients with active de novo or residual or recurrent intraocular retinoblastoma in at least one eye following completion of first-line therapy.

Timeline

Start: 2020-06-16
Primary completion: 2024-10-01
Completion: 2024-10-03

Publications

Gallie BL, Flegg K, Truong T, Liu J, Gavrylyuk Y, Chau K, Kletke S, Malliipatna A, Sheikh F, Soroka S, Ozkurt ZG, Alshahran N, Jong A, Janusonis I. Digital retinoblastoma documentation supports care and research. Can J Ophthalmol. 2025 Apr;60(2):100-106. doi: 10.1016/j.jcjo.2024.06.007. Epub 2024 Jul 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Topotecan	Small molecule	0.6 mg	Other
Subject	Topotecan	Small molecule	0.9 mg	Other
Subject	Topotecan	Small molecule	1.2 mg	Other
Subject	Topotecan	Small molecule	1.5 mg	Other
Subject	Topotecan	Small molecule	1.8 mg	Other

Topotecan Episcleral Plaque for Treatment of Retinoblastoma

Summary

Timeline

Publications

Drugs

Indications